Aileron Therapeutics Inc (NASDAQ:ALRN) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.75 and last traded at $2.09, with a volume of 1050 shares changing hands. The stock had previously closed at $2.16.
A number of research firms have issued reports on ALRN. ValuEngine raised Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research lowered Aileron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th.
The company has a debt-to-equity ratio of 0.10, a current ratio of 5.85 and a quick ratio of 5.85. The stock has a market cap of $31.68 million, a PE ratio of -1.19 and a beta of 0.04.
Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). On average, research analysts predict that Aileron Therapeutics Inc will post -2.34 earnings per share for the current year.
In other news, major shareholder Bioventures Ltd Novartis sold 20,388 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $2.30, for a total transaction of $46,892.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 52,281 shares of company stock worth $117,595 in the last ninety days. 16.10% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in Aileron Therapeutics stock. Millennium Management LLC lifted its holdings in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,658 shares of the company’s stock after acquiring an additional 105,073 shares during the period. Millennium Management LLC owned 0.84% of Aileron Therapeutics worth $670,000 at the end of the most recent reporting period. Institutional investors own 6.05% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Aileron Therapeutics (ALRN) Reaches New 12-Month Low at $1.75” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/11/06/aileron-therapeutics-alrn-reaches-new-12-month-low-at-1-75.html.
About Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.